Aileron Therapeutics Inc (NASDAQ:ALRN) Director Rickenbach Josef H. Von purchased 28,466 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were purchased at an average price of $0.72 per share, for a total transaction of $20,495.52. Following the completion of the purchase, the director now directly owns 68,352 shares of the company’s stock, valued at $49,213.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ ALRN traded up $0.04 during mid-day trading on Friday, hitting $0.82. The company had a trading volume of 264,736 shares, compared to its average volume of 269,559. The company has a market capitalization of $21.69 million, a PE ratio of -0.40 and a beta of 2.31. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.04 and a quick ratio of 6.04. Aileron Therapeutics Inc has a 1-year low of $0.44 and a 1-year high of $3.55. The business’s 50-day simple moving average is $0.61 and its 200 day simple moving average is $1.18.

Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, analysts expect that Aileron Therapeutics Inc will post -1.14 EPS for the current year.

ALRN has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Aileron Therapeutics in a research note on Wednesday, August 7th. ValuEngine upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research cut Aileron Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Aileron Therapeutics currently has a consensus rating of “Buy” and an average price target of $4.00.

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Aileron Therapeutics by 179.6% in the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock valued at $36,000 after acquiring an additional 31,787 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Aileron Therapeutics by 432.9% in the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock valued at $108,000 after acquiring an additional 104,932 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Aileron Therapeutics by 261.6% in the second quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock valued at $240,000 after acquiring an additional 240,910 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Aileron Therapeutics by 649.6% in the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock valued at $3,828,000 after acquiring an additional 1,768,073 shares in the last quarter. Institutional investors and hedge funds own 23.05% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Further Reading: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.